Biomarck

Jan 26, 2018

NC State Startup Biomarck Pharmaceuticals launches Phase 2 clinical trial for lung cancer treatment

Durham-based Biomarck Pharmaceuticals, a portfolio company of the North Carolina Biotechnology Center, has launched a Phase 2 clinical trial of a potential therapy for treating advanced non-small cell lung cancer (NSCLC).…

May 26, 2017

Child with Rare Cancer is First to Receive NC State Startup Biomarck Pharmaceuticals’ Drug

A new drug, discovered and developed in the Triangle, shows promise in treating cancer. It’s a story CBS North Carolina first reported on last year. At the time, the drug…

Apr 24, 2017

Biomarck Pharmaceuticals Gains FDA Allowance to Begin Human Trials for Inhaled Treatment for Adults with Lung Cancer

North Carolina based Biomarck Pharmaceuticals, Inc. has received FDA allowance l to begin human trials for their patented compound BIO-11006, for adults with lung cancer.  Discovered by Dr. Ken Adler…

Jan 24, 2017

Startup BioMarck Pharmaceuticals Featured on UNC-TV’s “NC Now”

Thursday’s episode of UNC-TV’s “NC Now,” included a segment titled “Aspirin of the Future,” about the development of a drug by Adler, a professor of cell biology at the North…